MoonLake Immunotherapeutics (MLTX) Current Leases (2022 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Current Leases of $920000.0 for Q1 2026, down 35.75% year-over-year from $1.4 million in Q1 2025, and down 25.45% quarter-over-quarter from $1.2 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Current Leases (2022 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $920000.0 for Q1 2026.
- In Q1 2026, Current Leases fell 35.75% year-over-year to $920000.0; the TTM figure through Mar 2026 stood at $920000.0 (down 35.75% YoY), while the FY2025 annual figure was $1.2 million, down 10.06% from the prior year.
- Current Leases for Q1 2026 stood at $920000.0, down from $1.2 million in the prior quarter.
- The five-year high for Current Leases was $1.5 million in Q2 2025, with the low at $153629.0 in Q4 2022.
- The 5-year median for Current Leases is $1.3 million (2024), against an average of $992805.9.
- The sharpest annual moves came in 2024 and 2026: Current Leases jumped 824.21% in 2024, then tumbled 35.75% in 2026.
- MoonLake Immunotherapeutics' Current Leases stood at $153629.0 in 2022, then soared by 679.72% to $1.2 million in 2023, then rose by 14.54% to $1.4 million in 2024, then fell by 10.06% to $1.2 million in 2025, then fell by 25.45% to $920000.0 in 2026.
- Business Quant data shows MLTX's Current Leases at $920000.0 in Q1 2026, $1.2 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | 920,000.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 156,338.00 |
| Jun 30, 2023 | 158,221.00 |
| Mar 31, 2023 | 155,173.00 |
| Dec 31, 2022 | 153,629.00 |